Speciality: Endocrinology
Description:
A warm welcome to all the medical practitioners in this interesting session on the first interchangeable US-approved biosimilar product- Glargine.
Insulin is a hormone secreted from the pancreas that helps blood sugar to enter the body's cells so it can be used for energy. Insulin also signals the liver to store blood sugar for later use. It is one of the important components that help in controlling diabetes in patients.
Biosimilar insulins are manufactured in living organisms (e.g., yeast and bacteria) to produce large quantities of the product, which limits the ability to manufacture exact replicas of original biological medications. Insulin glargine is a synthetic version of human insulin that is FDA-approved to treat adults and children. It is long-acting with the ability to control sugar all day long.
Insulin glargine, a product of Biocon, is the first interchangeable US FDA-approved biosimilar product, a long-acting, synthetic version of human insulin that works by replacing the normally produced insulin and by helping sugar to move out from the blood into other body tissues where it is used in the form of energy.
Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation